Oncology Knowledge into Practice Podcast

In today's episode, we welcome Dr. Sandip Patel, who is a Professor of Medical Oncology at the University of California, San Diego, to discuss the evolution of molecular profiling technology, focusing on how next-generation sequencing can help support patients with advanced thyroid cancer, but also how to integrate molecular profiling into clinical practice. Learning Objective(s): After comple...

In today's episode, we welcome Dr. Conor Steuer, which is Associate Professor at the Department of Hematology and Medical Oncology at Emory University School of Medicine in Atlanta, USA, to discuss adaptation of thyroid cancer guidelines to local care settings. We touch on strategies for guideline implementation and how to overcome potential barriers. Target Audience: Oncologists, pathologists...

Developments in precision medicine have led to a paradigm shift in the management of advanced thyroid cancer. The ESMO Guidelines Committee recently developed a new clinical practice guideline on the use of systemic therapy in this setting. This episode offers guideline insights into the applications recently approved therapies that have been approved by the FDA and/or the EMA, including cabozanti...

In today’s episode, we welcome expert Oncologist Dr. Claire Arthur and expert Endocrinologist Dr. Sarimar Agosto Salgado to discuss the challenges they have encountered and strategies that they have implemented to improve multidisciplinary collaboration in the management of patients with thyroid cancer and continued integration of precision medicine approaches. References 1. Fenton ME et al. Varia...

In today’s episode, we welcome Dr. Antonio Matrone, an endocrinologist at the University of Pisa, to discuss the many factors involved in treatment decision-making and strategies for the management of patients with advanced thyroid cancer where an oncogenic driver has been identified. References Matrone A et al. Differentiated thyroid cancer, from active surveillance to advanced therapy: Toward a...

In today’s episode, we welcome Principal Researcher Dr. David Tamborero who was integral to the development of the Molecular Tumor Board Portal to discuss the benefits associated with molecular tumor boards and the way in which the portal can support the discussions that take place at tumor board meetings, as well as how these initiatives can support the management of patients with thyroid cancer....

In today’s episode, we welcome expert Oncologist Dr. Lori Wirth and expert Pathologist Dr. Thomas Giordano to discuss the challenges they have encountered and strategies that they have implemented to improve multidisciplinary collaboration in the management of patients with thyroid cancer and continued integration of precision medicine approaches. References Kilagat K, Griffin MJ, Baik F, et al. T...

Liquid biopsy has emerged as a novel diagnostic tool, enabling rapid, non-invasive molecular testing of thyroid cancers. This episode offers insight into some of the opportunities and challenges that are presented by liquid biopsy in this field. To answer questions on this topic, we have invited Professor Frederique Penault-Llorca to join us. She is Professor of Pathology at the University of Cler...

Developments in RET-targeted therapies have led to a paradigm shift in the management of advanced thyroid cancer. However, resistance to these drugs has been observed to develop through a variety of mechanisms, so precise monitoring is required to detect and react to disease development. This episode offers insight into relevant mechanisms of resistance to RET inhibitors in thyroid cancer. It also...

Rearranged during transfection (RET) and tropomyosin receptor kinase (TRK) fusions are involved in various adult and paediatric cancers, including thyroid cancers. There is a high mortality rate for some of these cancers, partly due to the lack of efficient detection, diagnosis, and prognosis. The US and European guidelines recommend genomic testing as a part of standard diagnostic evaluations for...

In today’s episode, we’re going to talk about how precision medicine fits into thyroid cancer treatment guidelines. To answer our questions on this topic, we welcome the expertise of Dr. Lori Wirth. Dr. Wirth is Medical Director of the Center for Head and Neck Cancers at the Massachusetts General Hospital, and an Associate Professor in Medicine at Harvard Medical School. Funding statement: This in...

Precision medicine is a promising field that’s opening doors to novel therapeutics for many patients. But how does it fit into thyroid cancer specifically? What treatments are available or in the pipeline, for which patient subgroup, and what are the potential benefits? We’ll start off our series by exploring these questions, and we’ve invited Dr Eric Sherman, medical oncologist and thyroid cancer...

In this episode we speak with Dr Navel Daver, Associate Professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, USA, to get his thoughts on the highlights of ASCO and EHA for patients with MDS and AML. Funding Statement: This series is supported by educational grants from Servier Pharmaceuticals LLC and Takeda, who have had no influence on the content or choice of fac...

At the ASCO and EHA conferences, there were many interesting posters and presentations in the field of haemato-oncology. To share their conference highlights, we’ve invited our ALL expert Dr Dieter Hoelzer, director of internal medicine at the University of Frankfurt in Germany, and our MDS and AML expert Dr Amer Zeidan, Associate Professor Of Internal Medicine at the Yale University School Of Med...

Adult guidelines for acute myeloid leukaemia recommend determining a patient’s fitness before treating with standard therapy, but what does this mean, what are the implications, and how does this work in practice for both adults and children? To answer our questions on this topic, we’ve invited the expertise of Dr Courtney DiNardo, Associate Professor in the Department of Leukemia at The Universit...

Despite available treatments, many patients with acute myeloid leukaemia, or AML, are in need of additional therapeutic options. Thankfully, there hundreds of clinical trials for new interventions that could rectify this, but which options can we start to consider, for which patients and when? To answer our questions on this topic, we’ve invited the expertise of Dr Navel Daver, Associate Professor...

Although most commonly a disease of the old, Acute Myeloid Leukaemia is also a significant burden for younger patients, but it can present in different ways and they should not be treated equal. So how should younger and older patients be classified and treated? To help answer some of our questions on this topic is Dr. Tapan Kadia, Associate Professor in the Department of Leukemia at The Universit...

For patients with myelodysplastic syndrome, or MDS, their therapy options vary considerably depending on their prognosis and risk of developing AML. Today we discuss risk stratification systems and their rationale, and consider their utility in clinical practice. To answer our questions on this topic, we welcome Professor Detlaf Haase, medical director of the special diagnostic laboratories at the...

Last week we discussed the array of therapeutic options in the pipeline for patients with MDS. Today we shine a spotlight on NAE inhibitors, the first of which recently received FDA breakthrough designation to bring it to the clinic faster. To answer our questions about the current data and future therapeutic use for this novel class of drugs, we welcome Dr Magnus Tobiasson, senior consultant in i...

Despite available treatments, there is still an unmet need to improve outcomes for some patients with myelodysplastic syndrome, or MDS. Thankfully, there is a wide array of therapies in development that could fill this gap, but which therapies can we start to consider as real future options for which patients? To answer our questions on this topic, we’ve invited the expertise of invited Dr Amer Ze...

Myelodysplastic syndrome, or MDS is a rare blood disorder that often develops into acute myeloid leukaemia. Guideline recommendations can support treatment decisions for these patients, but some questions remain about best practice. In today’s episode, we’ve invited Dr Platzbecker, clinical director in the Hematology and Cellular Therapy department at the University Hospital Leipzig, Germany, to e...

We’re taking a break over the Christmas period, but we’ll be back in January with an exciting panel of experts discussing acute myeloid leukaemia, or AML. Until then, happy holidays and we'll see you in the new year!

Asparaginase is an important component of effective treatment strategies for adolescent and young adult patients with acute lymphoblastic leukaemia, but its associated adverse events must be effectively managed. To discuss this, we welcome Dr Dieter Hoelzer, Director of Internal Medicine and ALL specialist at the University of Frankfurt in Germany. Access more free education today! Visit the websi...

Adolescent and young adult patients with acute lymphoblastic leukaemia have been shown to benefit from paediatric inspired treatment regimens, however these regimens present unique challenges when it comes to adverse-event management. Today we’ve invited Dr Patrick Brown, Director of the Paediatric Leukaemia Programme at Johns Hopkins Medicine, Baltimore, to discuss how to reduce the risk of adver...

In our second episode on ALL we’ll be looking at adolescent and young adult (AYA) patients. Although these patients are commonly seen in the adult setting, evidence suggests that paediatric-inspired regimens may improve their outcomes. But how should these be implemented practically? Joining us this week is Dr Emily Curran, Assistant Professor in the Department of Medicine, Section of Hematology &...